Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The goal is to characterize vascular reactivity and cardiac pulsatility of normal appearing white matter in patients with CCM during hypercarbia/hypocarbia using quantitative real-time high-speed multi-echo fMRI to develop prognostic biomarkers for CCM formation
The MRI study sessions will be approximately 1 to 1.5 hours duration. Resting state fMRI will be performed using either eyes open or eyes closed condition while relaxing as much as possible without moving and thinking of anything. Task-based fMRI will be performed using specific study defined tasks. Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Patients already diagnosed with familial CCM. Suitable patients coming in the UNM CCM clinic will be contacted and requested to be a part of the study.
All familial CCM subjects presenting at UNMH who can consent to our study.
Adult Male/Female patients ages >18 years old
Individuals ages <18 year
Subjects with a known fear of dyspnea or enclosed spaces will be excluded from this study as well as those with metal implants, COPD, heart conditions, and hypercapnia.
Subjects who have contraindications to MRI such as harboring incompatible ferromagnetic objects implanted in the body.
Pregnant women (screening for pregnancy will be performed by oral questionnaire. MRI is safe in pregnancy but the study will exclude pregnant subjects, as the effects of respiratory challenge cannot be predicted in such subjects. Since these effects are proportional to the stage of gestation, oral history will be sufficient to assure safety.)
People unable to consent.
People unable to participate due to prior neurological deficits.
Subjects with underlying pre-existing pulmonary illness; such as asthma, COPD, pulmonary hypertension, will be excluded.
Cognitively impaired and/or participants not able to speak English language will not be included in the study (This pilot study involves performing motor and verbal tasks while in the MRI, in addition to undergoing a respiratory challenge, that requires understanding instructions clearly. We do not have current capabilities to include a translator who would be available at all stages of the study to include subjects who do not speak English.)
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
There would not be any plans in place to share IPD. All data will be de-identified and not linked to any individual participant.
Layout table for additional information
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemangioma, Cavernous, Central Nervous System
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Central Nervous System Vascular Malformations
Nervous System Malformations